Untitled case

This Inter Partes Review (IPR) concerns US Patent 11,840,730 and involves Unified Patents PTAB Data as the Petitioner and Molecular Loop Biosciences Inc. as the Patent Owner. Unified Patents is a member-based organization focused on deterring what it considers to be frivolous patent litigation and reducing assertions by Non-Practicing Entities (NPEs), also known as patent trolls, against operating companies by challenging patent validity through mechanisms like IPRs. Molecular Loop Biosciences Inc., the patent owner, is an operating company engaged in biotechnology, specifically in developing technologies for genetic analysis. The patent at issue, US 11,840,730, titled "Methods and compositions for evaluating genetic markers," describes techniques and compositions designed to enhance the accuracy and reproducibility of multiplex genetic analysis, particularly in detecting insertions or deletions within genomic regions containing nucleic acid repeats.

The case, IPR2024-01419, is proceeding before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) and has reached a Final Written Decision. The PTAB is an administrative body that reviews the patentability of claims in issued patents, offering an alternative forum to district courts for challenging patent validity. The decision of the PTAB can significantly impact the enforceability of the patent claims, potentially leading to their cancellation or affirmation, and can influence parallel district court litigation or licensing negotiations.

This IPR is notable due to its direct linkage to Unified Patents' overarching strategy to combat what it identifies as low-quality patent assertions. Unified Patents targets patents across various technology sectors, with an emphasis on those asserted by NPEs. Although Molecular Loop Biosciences Inc. appears to be an operating company, Unified Patents' decision to challenge their patent indicates a perceived risk or assertion pattern that falls within their deterrence goals. The patent's subject matter in genetic marker evaluation is also significant, touching upon critical areas within biotechnology, diagnostics, and personalized medicine.

Key Legal Developments and Outcome for IPR2024-01419

This analysis focuses on Inter Partes Review (IPR) proceeding IPR2024-01419, which concerns US Patent No. 11,840,730 B1 and has reached a Final Written Decision.

Parallel District Court Litigation

Filing of Infringement Complaint (June 10, 2024): Prior to the IPR petition, Patent Owner Molecular Loop Biosciences, Inc. filed a patent infringement lawsuit against Illumina, Inc. and others in the District of Delaware, case number 1:24-cv-00680. This litigation is currently pending.

Inter Partes Review (IPR2024-01419)

Patent at Issue: US Patent No. 11,840,730 B1, titled "Methods and compositions for evaluating genetic markers," owned by Molecular Loop Biosciences, Inc. The patent generally relates to methods for correcting errors and bias in nucleic acid analysis, particularly involving unique molecular identifiers or "differentiator tags."

Filing of IPR Petition (September 30, 2024): Illumina, Inc. (the defendant in the parallel district court case) filed a petition for inter partes review of claims 1-9 of the '730 patent. Although the prompt identifies "Unified Patents PTAB Data" as the plaintiff, official PTAB records list Illumina, Inc. as the Petitioner. Unified Patents often initiates IPRs on behalf of its members, which could explain the initial metadata.

Grounds for Challenge: Illumina, Inc. challenged claims 1-4 and 9 as anticipated by U.S. Patent No. 9,085,798 (Chee). Additionally, claims 1, 4-6, and 9 were challenged as obvious over Chee in view of Gahan et al. (Circulating Nucleic Acids in Plasma and Serum, ANN. N.Y. ACAD. SCI. 1137:1-6 (2008)), and also claims 1, 4-6, and 9 were challenged as obvious over U.S. Patent No. 8,053,192 (Bignell) in view of U.S. Patent Application Publication No. US2007/0020640 (McCloskey).

Institution of IPR (April 25, 2025): The Patent Trial and Appeal Board (PTAB) granted institution of the inter partes review for all challenged claims (1-9). The Board found that Illumina had demonstrated a reasonable likelihood of prevailing with respect to at least one challenged claim.

Claim Construction: In its institution decision, the PTAB considered the construction of terms such as "set of [unique] differentiator tags," proposing to construe it as "set of prepared tags where each tag includes a unique sequence as compared to the other tags." The PTAB generally uses the broadest reasonable interpretation standard for claim construction in IPRs.

Final Written Decision (FWD) (No specific date found, but expected between April and October 2026): While the prompt states the case reached a Final Written Decision, a precise date and outcome for IPR2024-01419's FWD were not found in the available search results. IPRs are typically concluded with a Final Written Decision within 12 to 18 months of institution. Given the institution date of April 25, 2025, the FWD would be expected between April 2026 and October 2026. Without the specific FWD document, the outcome of the IPR (e.g., claims found unpatentable or patentable) cannot be definitively stated.

Effect on Litigation

The parallel district court litigation (Molecular Loop Biosciences, Inc. v. Illumina, Inc. et al., No. 1:24-cv-00680 (D. Del.)) was noted by the PTAB in its institution decision. District courts often consider staying litigation pending the outcome of an IPR, especially if the IPR is instituted and is likely to address the validity of the asserted claims. The PTAB itself may deny institution if a parallel district court case is likely to reach a validity decision before the IPR's Final Written Decision deadline, although this was not the case here as institution was granted. The outcome of the FWD in IPR2024-01419 would have a significant impact on the district court case, potentially leading to a stay, settlement, or influencing the litigation's scope based on the patentability of the challenged claims.

Appeal: Information regarding an appeal of the Final Written Decision to the U.S. Court of Appeals for the Federal Circuit for IPR2024-01419 is not available in the provided search results, likely because the specific FWD date and outcome are not yet publicly detailed, and appeals typically follow the FWD. Appeals to the Federal Circuit must generally be filed no later than 63 days after the date of the final written decision.

Counsel of Record for IPR2024-01419 Not Publicly Available

Correction: The proceeding IPR2024-01419 is an Inter Partes Review (IPR) before the Patent Trial and Appeal Board (PTAB), not a patent infringement case. The petitioner in this IPR is Illumina, Inc., and the patent owner is Molecular Loop Biosciences, Inc.. The initial prompt incorrectly identified "Unified Patents PTAB Data" as the plaintiff.

As of the current date, the specific counsel of record representing Illumina, Inc. (the petitioner) in IPR2024-01419 are not explicitly identified in the publicly available search results, including the CaseMine entry for the IPR. The CaseMine entry specifically states, "ATTORNEY(S) ACTS. No Acts.". This indicates that detailed attorney information for this particular IPR is not readily accessible through the performed web searches.

While Illumina, Inc. employs in-house intellectual property counsel such as Yan Leychkis (Senior Director, Global Intellectual Property) based in San Diego, CA, and has had individuals like Charles E. Dadswell (former Senior Vice President, General Counsel and Secretary) and Scott Davies (acting General Counsel) in leadership legal roles, their direct involvement as counsel of record for IPR2024-01419 has not been specified.

Similarly, mentions of outside counsel representing Illumina in other patent litigation matters, such as Kelly Farnan of Richards, Layton & Finger in a Delaware District Court case, or attorneys from Quinn Emanuel Urquhart & Sullivan, LLP in a case where Illumina was a defendant, do not link them to IPR2024-01419. Joshua Fougere of Sidley Austin LLP was granted pro hac vice approval for Illumina in a related Delaware district court case, but this is distinct from the IPR proceeding itself.

Therefore, based on the available information, the specific counsel of record for Illumina, Inc. in IPR2024-01419 cannot be identified at this time. Filings for IPRs are typically publicly accessible via the PTAB's Patent Trial and Appeal Case Tracking System (P-TACTS), but specific attorney listings for this case were not found in the search results.

This IPR proceeding, IPR2024-01419, involves Unified Patents PTAB Data as the Petitioner and Molecular Loop Biosciences Inc. as the Patent Owner. While Unified Patents is the petitioner, the underlying district court litigation identifies Illumina, Inc. as the real party-in-interest for the IPR and the entity that filed the petition. Molecular Loop Biosciences Inc. is the patent owner.

Based on available information, the following counsel are identified as representing the parties in related proceedings or generally for the entities involved:

Counsel for Molecular Loop Biosciences Inc. (Patent Owner):

• Brian Matty
  • Role: Counsel for Molecular Loop's patent licensing program (in a related district court case).
  • Firm: Desmarais LLP.
  • Note: Quoted regarding Molecular Loop's preference for licensing but willingness to litigate patent infringement.

While a specific legal team for Molecular Loop Biosciences Inc. in IPR2024-01419 could not be definitively identified through the provided search snippets, Brian Matty of Desmarais LLP is noted as counsel for Molecular Loop in related patent litigation.

Counsel for Unified Patents PTAB Data (Petitioner, with Illumina, Inc. as Real Party-in-Interest):

While Unified Patents is the named petitioner, Illumina, Inc. is identified as the real party-in-interest in this IPR.

• Jonathan Stroud

  • Role: COO & CLO, Unified Patents. General Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).
  • Note: Manages Unified Patents' legal and corporate work, focusing on PTAB, district court, and appellate litigation. Previously a patent attorney at Finnegan, Henderson, Farabow, Garrett and Dunner LLP, and a patent examiner at the USPTO.

• Jenn Bisk

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

• Kyla Bulter

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

• Kelly Hughes

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

• Patrick King

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

• T.J. Murphy

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

• Vinu Raj

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

• Jordan Rossen

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

• David Seastrunk

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

• Andrea Shoffstall

  • Role: Senior Patent Counsel, Unified Patents.
  • Firm: Unified Patents (in-house).

While Unified Patents often handles IPRs internally, they may also engage outside counsel. For instance, Brian W. Oaks of Baker Botts, L.L.P. has represented Unified Patents in other IPR proceedings. However, no specific outside counsel has been identified in the provided snippets for IPR2024-01419.

For the real party-in-interest, Illumina, Inc., Joshua Fougere of Sidley Austin LLP was granted pro hac vice approval in a related district court case, suggesting his involvement in the broader litigation strategy, though his direct role in this specific IPR is not confirmed by the provided information.